Publicaciones Científicas

1.

Carbonell X, Botet F, Figueras J, Álvarez E, Riu A. The incidence of breastfeeding in our environment. J. Perinat. Med 1998;26:320-324.

2.

Carbonell X, Guiffré L, Kimmpen Sletal. Guidelines for the use of Palivizumab in prevention of RSV disease in infant. Infections in Medecine; December 1999.

3.

Carbonell X, Quero J, Bustos G et al. Rehospitalization due to respiratory syncytine vivus infection in premature infants under 33 week gestational age.A prospective study. Pediatrics Infectious Disease Journal 2000; 18: 592-597.

4.

Barbara J. Law and Xavier Carbonell, MD, PhD. Epidemiology of respiratory syncytial virus disease. The Journal of Respiratory Disease; Vol. 2, NO. 4 Supplement, November 2000; 10-16

5.

Carbonell X, Botet F, Figueras, Riu A. Prediction of hyperbilirubinaemia in the healty term newborn. Acta Paediatrica, Feb 90 (2):166-170. 2001

6.

J.Figueras, J Quero, X Carbonell-Estrany. Early administration of a second dose of surfactant in treatment of severe hyaline membrane disease. Acta Paediatrica, 2001:90:296-301.

7.

X Carbonell-Estrany, J Quero and the IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive years. Pediatric Infectious Disease Journal. 2001;20:874-879.

8.

M.D. Salvia, L. García, A. Goncé, M.T. Esqué, J. Figueras, X. Carbonell. Convulsiones y hemorragia subaracnoidea tras exposición a paroxetina in utero. Rev. Neurol 2001; 33 () y Rev. Neurol 2003; 36 (8): 724-726.

9.

X Carbonell-Estrany, J Figueras. Anemia of Prematurity: treatment with erythropoietin. Review. Early Human Development 2002;65:S63-S67.

10.

B.J. Law, X. Carbonell-Estrany and E.A.F Simoes. An update on Respiratory Syncytial. Virus epidemiology : a developed country perspective. Respiratory Medecine March 2002; Vol. 96, Sup. B (SL).

11.

X. Carbonell and J. LL. Kimpen. RSV and RAD : posibilitéis for prevention. The link between respiratory syncytial virus and reactive airway disease. Respir Res 2002, 3 (suppl 1): S1-S2.

12.

J. Figueras, L. Gómez, J.M. Rodríguez-Miguélez, Y. Jordán, M.D. Salvia, W. Jiménez, X. Carbonell. Plasma nitrite/nitrate and endothelin-1 concentrations in neonatal. Acta Paediatr 92; 582-587. 2003.

13.

J. Figueras, Y. Jordán, J.M. Rodríguez-Miguélez, W. Jiménez, F. Botet, X. Carbonell, R. Jiménez. Expired Nitric Oxide in the Newborn with High Risk of Perinatal Infection. American Journal of Perinatology 2003, Vol. 20, Núm. 3

14.

E.A.F. Simoes, X. Carbonell. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr. Infect. Dis J. 2003; 22:S13-20.

15.

X. Carbonell. Palivizumab Outcomes Registry Data from Spain : Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group. Pediatr. Infect. Dis J. 2003; 22:S55-7.

16.

López-Sastre JB, Coto GD, Fernández B, Carbonell FX , Figueras J . Neonatal invasive candidiasis: A prospective multicenter study of 118 cases. Am J Perinat 2003; 20:153-163.

17.

Pedraz C, Carbonell FX , Figueras J , Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003; 22: 823-82

18.

Figueras-Aloy J, Gómez-López L, Rodríguez-Miguélez JM, Jordán-García Y, Salvia-Roigés MªD, Jiménez W, Carbonell-Estrany X. Plasma endothelin-1 and clinical manifestations of neonatal sepsis. J. Perinat. Med 2004; 32: 522-526.

19.

Carbonell-Estrany X, Figueras-Aloy J and the Infección Respiratoria Infantil por Virus Respiratorio Sincitial Study Group, and J. Law B, MD and the Pediatric Investigators Collaborative Network on Infections in Canada Study Group., Identitying Risk Factors for Severe Respiratory Syncytial Virus Among Infants Born After 33 Through 35 Completed Weeks of Gestation. The Pediatric Infectious Disease Journal 2004; 23, núm. 11: S193-S201

20.

Vicente-Gutiérrez MP, Castelló-Almazán I, Salvia-Roigés MD, Rodríguez-Miguélez JM, Vives-Corrons MD, Figueras-Aloy J, Carbonell-Estrany X. Perinatal/Neonatal Case Presentation : Nonimmune Hydrops Fetalis due to Congenital Xerocytosis. Journal of Perinatology 2005; 25:63-65

21.

Carbonell Estrany, FX , Figueras Aloy J , Alvarez Domínguez E . Erythropoietin and prematurity - where do we stand?. J Perinat Med 2005; 33: 277-286. I.F.:0,79.

22.

Figueras J , Moro M, Pérez J, Fernández C, Roqués V, Quero J, Jiménez R , Carbonell FX . Antenatal Glucocorticoid Treatment Decreases Mortality and Chronic Lung Disease in Survivors among 23- to 28- Week Gestational Age Preterm Infants. Am J Perinat 2005; 22: 441-448. I.F.: 0,859.

23.

Pascual N, Herrero S, Salvia MD , Rodríguez-Miguélez JM , Figueras J , Carbonell FX . Repercusión fetal y neonatal del shock anafilático materno. Acta Pediatr Esp 2005; 63: 283-285.

24.

Alsina L, Esteban M, Salvia MD, Rodríguez-Miguélez JM, Figueras J, Carbonell X. Severe Hypernatremic Dehydration Secondary to Undetected Lactation Failure : Usefulness of Sodium Levels in Breast Milk. Clinical Pediatrics 2006;45:183-186

25.

Carbonell X. Coautor amb la Conselleria de Sanitat. Generalitat de Catalunya 2006. Protocol Hospitalari d'Assistència domiciliària per a nadons preterme o baix pes. Conselleria de Sanitat. Generalitat de Catalunya 2006.

26.

SimoesE, Carbonell-Estarny X. Palivizumab Prophylaxis, Respiratory Syncytial Virus and Subsequent Recurrent Wheezing. The Journal of Pediatrics August 2007

27.

Figueras J , Gómez L, Rodríguez-Miguélez JM , Salvia M , Jordán I, Ferrer I, Carbonell FX , Jiménez R. Serum Soluble ICAM-1, VCAM-1, L- Selectin, and P-Selectin Levels as Markers of Infection and their Relation to Clinical Severity in Neonatal Sepsis. Am J Perinat 2007; 24: 331-338.

28.

Coll O, Menendez C, Botet F, Dayal R, and the WAPM Perinatal Infections Working Group: Xavier Carbonell-Estrany, Leonard E, Weisman M, Anceschi M, Greenough A, Gibs R, Ville y. Treatment and prevention of malaria in pregnancy and newborn. J. Perinat. Med. 36 (2008) 15-29.

29.

Carbonell-Estrany X, Figueras J, Salcedo S, De la Rosa M, Castrillo Study Group. Probable early-onset group B streptococcal neonatal sepsis: a serious clinical condition related to intrauterine infection. Arch. Dis Chile Fetal Neonatal. Ed 2008, 93: F85-F89.

30.

Coll O, Menendez C, Botet F, Dayal R; World Association of Perinatal Medicine Perinatal Infections Working Group, Carbonell-Estrany X, Weisman LE, Anceschi MM, Greenough A, Gibss RS, Ville Y. Treatment and prevention of malaria in pregnancy and newborn. J Perinat Med. 2008;36(1):15-29.PMID: 18184095

31.

Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants >or=35 weeks gestation. Bhutani VK, Maisels MJ, Stark AR, Buonocore G; Expert Committee for Severe Neonatal Hyperbilirubinemia; European Society for Pediatric Research; American Academy of Pediatrics. Neonatology. 2008;94(1):63-7. Epub 2008 Jan 17

32.

Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O'Brien K, Allen U, Mitchell I, Aloy JF, Pedraz C, Michaliszyn AF. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making. 2008 Jul-Aug;28(4):471-80. Epub 2008 Jun 12

33.

Miracle X, Di Renzo GC, Stark A, Fanaroff A, Carbonell-Estrany X, Saling E; Coordinators Of World Associatin of Perinatal Medicine Prematurity Working Group. Guideline for the use of antenatal corticosteroids for fetal maturation. J Perinat Med. 2008;36(3):191-6.

34.

Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, Lanari M. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):891-9. Epub 2008 Jul 16. Review

35.

Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, Doménech-Martínez E; IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008 Sep;27(9):788-93.

36.

Figueras-Aloy J, Berrueco R, Salvia-Roiges MD, Rodríguez-Miguélez JM, Miracle-Echegoyen X, Botet-Mussons F, Mur-Sierra A, Vall O, Carbonell-Estrany X. Attempt to normalize simulated exhaled nitric oxide according to ventilatory settings. Pediatr Pulmonol. 2008 Dec;43(12):1167-74.

37.

Simões EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, Guzman J; European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res. 2008 Dec 8;9:78.

38.

Figueras-Aloy J, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, Doménech-Martínez E; Grupo IRIS. Usefulness of different risk factor associations in predicting admissions due to respiratory syncytial virus in premature newborns of 32 to 35 weeks gestation in Spain. An Pediatr (Barc). 2009 Jul;71(1):47-53. Epub 2009 Jun 12. Spanish.

39.

Carbonell-Estrany X, Lázaro y de Mercado P. Health economics and RSV. Paediatr Respir Rev. 2009 Jun;10 Suppl 1:12-3. Review.

40.

Coll O, Benoist G, Ville Y, Weisman LE, Botet F, Anceschi MM, Greenough A, Gibbs RS, Carbonell-Estrany X; WAPM Perinatal Infections Working Group. Guidelines on CMV congenital infection. J Perinat Med. 2009;37(5):433-45

41.

Figueras-Aloy J, Rodríguez-Miguélez JM, Iriondo-Sanz M, Salvia-Roiges MD, Botet-Mussons F, Carbonell-Estrany X. Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics. 2010 Jan;125(1):139-44. Epub 2009 Nov 30.

42.

Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA; Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010 Jan;125(1):e35-51. Epub 2009 Dec 14

43.

Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simões EA. POPULATION BASED EXTERNAL VALIDATION OF A EUROPEAN PREDICTIVE MODEL FOR RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATION OF PREMATURE INFANTS BORN 33 TO 35 WEEKS OF GESTATIONAL AGE. Pediatr Infect Dis J. 2009 Dec 15. [Epub ahead of print]

44.

Arca G, Botet F, Palacio M, Carbonell-Estrany X. Timing of umbilical cord clamping: New thoughts on an old discussion. J Matern Fetal Neonatal Med. 2010 Jan 11. [Epub ahead of print]

45.

Botet F, Figueras J, Carbonell-Estrany X, Arca G, The Castrillo Study Group. Effect of maternal clinical chorioamnionitis on neonatal morbidity in very-low birthweight infants: a case-control study. J Perinat Med. 2010 Feb 2.

46.

Carbonell-Estrany X, Simões EA, Fullarton JR, Ferdynus C, Gouyon JB. Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation. J Perinat Med. 2010 Mar 18. [Epub ahead of print]

47.

Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M; European RSV Risk Factor Study Group. European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data. J Matern Fetal Neonatal Med. 2011 Jan;24(1):152-7. doi: 10.3109/14767058.2010.482610. Epub 2010 May 21.Reviewer last years 2003-2009

48.

Figueras Aloy J, Carbonell Estrany X; Comité de Estándares de la Sociedad Española de Neonatología. Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation). An Pediatr (Barc). 2010 Aug;73(2):98.e1-4. doi: 10.1016/j.anpedi.2010.05.026. Epub 2010 Jul 10. Spanish

49.

Simões EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR; Palivizumab Long-Term Respiratory Outcomes Study Group. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol. 2010 Aug;126(2):256-62. doi: 10.1016/j.jaci.2010.05.026. Epub 2010 Jul 10

50.

Moltó-Puigmartí C, Castellote AI, Carbonell-Estrany X, López-Sabater MC. Differences in fat content and fatty acid proportions among colostrum, transitional, and mature milk from women delivering very preterm, preterm, and term infants. Clin Nutr. 2011 Feb;30(1):116-23. doi: 10.1016/j.clnu.2010.07.013. Epub 2010 Aug 25

51.

Alvarez Domínguez E, Pérez Fernández JM, Figueras Aloy J, Carbonell Estrany X. Erythropoietin treatment for late anaemia after haemolytic disease of the newborn. An Pediatr (Barc). 2010 Dec;73(6):334-9. doi: 10.1016/j.anpedi.2010.09.002. Epub 2010 Oct 20.

52.

Figueras-Aloy J, Salvia-Roiges MD, Rodriguez-Miguélez JM, Miracle-Echegoyen X, Botet-Mussons F, Marín-Soria JL, Carbonell-Estrany X. Impact of chorioamnionitis on exhaled nitric oxide and endotracheal aspirate levels of nitrites-nitrates and interleukin-8 in mechanically ventilated preterm neonates. Pediatr Pulmonol. 2011 Jun;46(6):595-603. doi: 10.1002/ppul.21410. Epub 2011 Jan 18.

53.

Botet F, Figueras J, Carbonell-Estrany X, Narbona E. The impact of clinical maternal chorioamnionitis on neurological and psychological sequelae in very-low-birth weight infants: a case-control study. J Perinat Med. 2011 Mar;39(2):203-8. doi: 10.1515/JPM.2011.005. Epub 2011 Feb 7

54.

Costa-Orvay JA, Figueras-Aloy J, Romera G, Closa-Monasterolo R, Carbonell-Estrany X. The effects of varying protein and energy intakes on the growth and body composition of very low birth weight infants.

55.

Manzoni P, Paes B, Resch B, Carbonell-Estrany X, Bont L. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Hum Dev. 2012 May;88 Suppl 2:S34-41. doi: 10.1016/S0378-3782(12)70012-9. Erratum in: Early Hum Dev. 2012 Oct;88(10):845. Mejias, A [removed]; Ramilo, O [removed]

56.

Botet F, Figueras-Aloy J, Miracle-Echegoyen X, Rodríguez-Miguélez JM, Salvia-Roiges MD, Carbonell-Estrany X. Trends in survival among extremely-low-birth-weight infants (less than 1000 g) without significant bronchopulmonary dysplasia. BMC Pediatr. 2012 Jun 8;12:63. doi: 10.1186/1471-2431-12-63

57.

Carbonell-Estrany X, Fullarton JR, Gooch KL, Vo PG, Figueras-Aloy J, Lanari M, Gouyon JB, Liese JG. Effects of parental and household smoking on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm infants and the potential impact of RSV prophylaxis. J Matern Fetal Neonatal Med. 2013 Jun;26(9):926-31. doi: 10.3109/14767058.2013.765850. Epub 2013 Feb 12

58.

Carbonell-Estrany X, Fullarton JR, Rodgers-Gray BS, Gooch KL, Vo PG, Figueras-Aloy J. Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32-35 weeks' gestational age with more informed use of risk factors? J Matern Fetal Neonatal Med. 2014 Aug 14:1-9. ;http://informahealthcare.com/jmf ; ISSN: 1476-7058 (print), 1476-4954 (electronic)

59.

Alvarez Miró R, Lluch Canut MT, Figueras Aloy J, Esqué Ruiz MT, Arroyo Gili L, Bella Rodríguez J, Carbonell Estrany X. [Influence of in-home nursing care on the weight of the early discharged preterm newborn.] An Pediatr (Barc). 2014 Feb 27. pii: S1695-4033(13)00428-1. doi: 10.1016/j.anpedi.2013.10.024. [Epub ahead of print] Spanish

60.

Di Renzo GC, Meli P, Beyardi A, Blennow M, Carbonell-Estrany X, Donzelli GP, Hakansson S, Hod M, Hughes R, Kurtzer M, Poyart C, Shinwel E, Stray-Pedersen B,Wielgos M, El Helali N. Intrapartum GBS screening and antibiotic prophylaxis:a European consensus conference. J Materno Fetal Neonatal Med. 2014 Early on line :1-17. DOI: 10.3109/14767058.2014.934804. http://informahealthcare.com/jmf;ISSN:1476-7058 (print), 1476-4954 (electronic)

61.

Carbonell-Estrany X. Parental and Family Burden of Respiratory Syncytial Virus (RSV) Infections- Xavier . Cure&Care: Journal of Neonatal Intensive Care Jan 5, 2015

62.

Figueras Aloy J, Carbonell Estrany X [Update of recommendations on the use of palivizumab as prophylaxis in RSV infections]. Comité de Estándares de la SENeo.An Pediatr (Barc). 2015 Mar;82(3):199.e1-2. doi: 10.1016/j.anpedi.2014.10.004. Epub 2014 Nov 11. Spanish

63.

Carbonell-Estrany X, Pérez-Yarza EG, García LS, Guzmán Cabañas JM, Bòria EV, Atienza BB; IRIS Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants-The SPRING Study.(Infección Respiratoria Infantil por Virus Respiratorio Sincitial) Study Group.PLoS One. 2015 May 8;10(5):e0125422. doi: 10.1371/journal.pone.0125422. eCollection 2015

64.

Simoes EA, Carbonell-Estrany X, Guilbert T, Mansbach JM, Piedra PA, Ramilo O, Welliver R Sr. Clinical Endpoints for Respiratory Syncytial Virus Prophylaxis Trials in Infants and Children in High and Middle Income Countries. Pediatr Infect Dis J. 2015 Jun 26. [Epub ahead of print] PMID: 26121204 [PubMed - as supplied by publisher]

65.

Figueras-Aloy J, Manzoni P, Paes B, Simões EA, Bont L, Checchia PA, Fauroux B, Carbonell-Estrany X.Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease. Infect Dis Ther. 2016 Sep 14. [Epub ahead of print] Review. PMID: 27628014

66.

Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, Simões EA, Carbonell-Estrany X. Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries.Infect Dis Ther. 2016 Sep;5(3):271-98. doi: 10.1007/s40121-016-0123-0. Epub 2016 Aug 1. Review. PMID:27480325

67.

Carbonell-Estrany X, Fullarton JR, Gooch KL, Gouyon JB, Lanari M, Rodgers-Gray BS, Thwaites RJ, Vo PG, Liese JG. The influence of birth weight amongst 33-35 weeks gestational age (wGA) infants on the risk of respiratory syncytial virus (RSV) hospitalisation: a pooled analysis.J Matern Fetal Neonatal Med. 2016 Apr 6:1-7. [Epub ahead of print] PMID: 26965584

68.

Figueras Aloy J, Esqué Ruiz MT, Arroyo Gili L, Bella Rodriguez J, Álvarez Miró R, Carbonell Estrany X. [Changes in homecare for preterm and low-birth-weight infants from 2002 to 2014]. An Pediatr (Barc). 2016 Sep;85(3):134-41. doi: 10.1016/j.anpedi.2016.01.022. Epub 2016 Mar 3. Spanish.PMID: 26947096

69.

Checchia PA, Paes B, Bont L, Manzoni P, Simões EA, Fauroux B, Figueras-Aloy J, Carbonell-Estrany X. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease. Infect Dis Ther. 2017 Mar;6(1):37-56. doi: 10.1007/s40121-016-0142-x. Review. PMID: 28070870 [PubMed - in process] Free PMC Article

70.

Paes B, Fauroux B, Figueras-Aloy J, Bont L, Checchia PA, Simões EA, Manzoni P, Carbonell-Estrany X Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus infection Among Infants with Chronic Lung Disease. Infect Dis Ther. 2016 Dec;5(4):453-471. Review. PMID: 27864751 [PubMed - in process] Free PMC Article

71.

Anderson EJ, Carbonell-Estrany X, Blanken M, Lanari M, Sheridan-Pereira M, Rodgers-Gray B, Fullarton J, Rouffiac E, Vo P, Notario G, Campbell F, Paes B Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons. Pediatr Infect Dis J. 2017 Feb;36(2):160-167. doi: 10.1097/INF.0000000000001377.PMID: 27755464 [PubMed - in process] Free PMC Article

72.

Manzoni P, Figueras-Aloy J, Simões EAF, Checchia PA, Fauroux B, Bont L, Paes B, Carbonell-Estrany X. Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases. Infect Dis Ther. 2017 Sep;6(3):383-411. doi: 10.1007/s40121-017-0160-3. Epub 2017 Jun 26. Review. PMID:28653300 Free PMC Article

73.

Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martinón-Torres F, Carbonell-Estrany X. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect Dis. 2017 Oct 17;17(1):687. doi: 10.1186/s12879-017-2803-0. PMID:29041909 Free PMC Article

74.

Fauroux B, Simões EAF, Checchia PA, Paes B, Figueras-Aloy J, Manzoni P, Bont L, Carbonell-Estrany X. The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood. Infect Dis Ther. 2017 Jun;6(2):173-197. doi: 10.1007/s40121-017-0151-4. Epub 2017 Mar 29. Review. PMID:28357706 Free PMC Article

75.

Blanken MO, Paes B, Anderson EJ, Lanari M, Sheridan-Pereira M, Buchan S, Fullarton JR, Grubb E, Notario G, Rodgers-Gray BS, Carbonell-Estrany X. Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants. Pediatr Pulmonol. 2018 Feb 6. doi: 10.1002/ppul.23960. PMID:29405612

76.

Simões EAF, Bont L, Manzoni P, Fauroux B, Paes B, Figueras-Aloy J, Checchia PA, Carbonell-Estrany X.UI Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018 Feb 22. doi: 10.1007/s40121-018-0188-z. Review. PMID:29470837 Free PMC Article

77.

Carbonell-Estrany X, Dall'Agnola A, Fullarton JR, Rodgers-Gray BS, Girardi E, Mussa A, Paniagua N, Pieretto M, Rodríguez-Fernandez R, Manzoni P. Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV Outcomes Study [EROS]). Acta Paediatr. 2018 Jan 17. doi: 10.1111/apa.14224. PMID:29341239

78.

Luna MS, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A, Chawla R, Dotta A, Fernández RR, Resch B, Carbonell-Estrany X Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev. 2018 Dec 18. pii: S1526-0542(18)30139-8. doi: 10.1016/j.prrv.2018.12.001. Review.PMID:31060948

79.

Carbonell-Estrany X RSV prevention in infancy and asthma in later life. Lancet Respir Med. 2018 Jul;6(7):e31. doi: 10.1016/S2213-2600(18)30229-7. No abstract available. PMID:29976447

80.

Paes B, Carbonell-Estrany X Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right? Expert Rev Anti Infect Ther. 2019 Apr;17(4):211-222. doi: 10.1080/14787210.2019.1581062. Epub 2019 Feb 26.PMID:30739513

81.

Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries. Carbonell-Estrany X, Rodgers-Gray BS, Paes B. Expert Rev Anti Infect Ther. 2020 Sep 24. doi: 10.1080/14787210.2021.1828866. Online ahead of print. PMID: 32972198

82.

Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies. Lanari M, Anderson EJ, Sheridan-Pereira M, Carbonell-Estrany X, Paes B, Rodgers-Gray BS, Fullarton JR, Grubb E, Blanken M. Epidemiol Infect. 2020 Aug 17;148:e170. doi: 10.1017/S0950268820001661. PMID: 32799945

83.

Exploring respiratory syncytial virus prophylaxis for children with all grades of bronchopulmonary dysplasia. Paes B, Baraldi E, Fauroux B, Carbonell-Estrany X. Acta Paediatr. 2020 Jul 21. doi: 10.1111/apa.15482. Online ahead of print. PMID: 32691906

84.

Extrauterine growth restriction in very preterm infant: etiology, diagnosis, and 2-year follow-up. Figueras-Aloy J, Palet-Trujols C, Matas-Barceló I, Botet-Mussons F, Carbonell-Estrany X. Eur J Pediatr. 2020 Sep;179(9):1469-1479. doi: 10.1007/s00431-020-03628-1. Epub 2020 Mar 19. PMID: 3219365

85.

Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries.Carbonell-Estrany X, Rodgers-Gray BS, Paes B. Expert Rev Anti Infect Ther. 2021 Apr;19(4):419-441. doi: 10.1080/14787210.2021.1828866. Epub 2020 Dec 8. PMID:32972198 Review.

86.

Exploring respiratory syncytial virus prophylaxis for children with all grades of bronchopulmonary dysplasia.Paes B, Baraldi E, Fauroux B, Carbonell-Estrany X. Acta Paediatr. 2021 Jan;110(1):25-27. doi: 10.1111/apa.15482. Epub 2020 Aug 3. PMID: 32691906 No abstract available.

87.

Accurately Assessing the Expected Impact of Universal First RSV Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants.Fullarton J, Keary I, Paes B, Tarride JE, Carbonell-Estrany X, Rodgers-Gray B. J Infect Dis. 2022 Dec 15:jiac488. doi: 10.1093/infdis/jiac488. Online ahead of print.PMID: 36520978 No abstract available.

88.

Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.Carbonell-Estrany X, Simões EAF, Bont LJ, Gentile A, Homaira N, Scotta MC, Stein RT, Torres JP, Sheikh J, Broor S, Khuri-Bulos N, Nokes DJ, Munywoki PK, Bassat Q, Sharma AK, Basnet S, Garba M, De Jesus-Cornejo J, Lupisan SP, Nunes MC, Divarathna M, Fullarton JR, Rodgers-Gray BS, Keary I, Reñosa MDC, Verwey C, Moore DP, Noordeen F, Kabra S, do Vale MS, Paternina-De La Ossa R, Mariño C, Figueras-Aloy J, Krilov L, Berezin E, Zar HJ, Paudel K, Safadi MAP, Dbaibo G, Jroundi I, Jha R, Rafeek RAM, Pinheiro RS, Bracht M, Muthugala R, Lanari M, Martinón-Torres F, Mitchell I, Irimu G, Pandey A, Krishnan A, Mejias A, da Costa MSC, Shrestha S, Pernica JM, de Carvalho FC, Jalango RE, Ibrahim H, Ewa A, Ensinck G, Ulloa-Gutierrez R, Miralha AL, Lucion MF, Hassan MZ, Akhtar Z, Aleem MA, Chowdhury F, Rojo P, Sande C, Musau A, Zaman K, Helena L, Arlant F, Ghimire P, Price A, Subedi KU, Brenes-Chacon H, Goswami DR, Rahman MZ, Hossain ME, Chisti MJ, Vain NE, Lim A, Chiu A, Papenburg J, Juarez MDV, Senaratne T, Arunasalam S, Strand TA, Ayuk A, Ogunrinde O, Tavares LVS, Garba C, Garba BI, Dawa J, Gordon M, Osoro E, Agoti CN, Nyawanda B, Ngama M, Tabu C, Mathew JL, Cornacchia A, Rai GK, Jain A, et al. Front Pediatr. 2022 Nov 9;10:1033125. doi: 10.3389/fped.2022.1033125. eCollection 2022. PMID:36440349 Free PMC article.

89.

Nosocomial RSV-related In-hospital Mortality in Children <5 Years: A Global Case Series.Löwensteyn YN, Willemsen JE, Mazur NI, Scheltema NM, van Haastregt NCJ, Buuren AAAT, van Roessel I, Scheepmaker D, Nair H, van de Ven PM, Bont LJ; on behalf of the RSV GOLD Study Group. Pediatr Infect Dis J. 2023 Jan 1;42(1):1-7. doi: 10.1097/INF.0000000000003747. Epub 2022 Nov 8. PMID: 36476518 Free PMC article.

90.

Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants.Paes B, Fullarton JR, Rodgers-Gray BS, Carbonell-Estrany X. Curr Med Res Opin. 2021 Jul;37(7):1149-1153. doi: 10.1080/03007995.2021.1911974. Epub 2021 Apr 21. PMID: 33813989

91.

Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.Rodgers-Gray BS, Fullarton JR, Carbonell-Estrany X, Keary IP, Tarride JÉ, Paes BA. J Med Econ. 2023 Apr 17:1-53. doi: 10.1080/13696998.2023.2202600. Online ahead of print. PMID: 37067826

92.

Prioritising respiratory syncytial virus prevention in low-income and middle-income countries.Carbonell-Estrany X, Simões EA, Bont LJ, Paes BA; RSV Prevention Collaborators. Lancet Glob Health. 2023 May;11(5):e655-e657. doi: 10.1016/S2214-109X(23)00165-1. PMID: 37061306 Free article. No abstract available.

93.

Keary IP, Ravasio R, Fullarton JR, Manzoni P, Lanari M, Paes BA, Carbonell-Estrany X, Baraldi E, Tarride JÉ, Rodgers-Gray B. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age. PLoS One. 2023 Aug 10;18(8):e0289828. doi: 10.1371/journal.pone.0289828.

94.

Fullarton J, Keary I, Paes B, Tarride JE, Carbonell-Estrany X, Rodgers-Gray B. Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants. J Infect Dis. 2023 May 29;227(11):1333-1334. doi: 10.1093/infdis/jiac488.

95.

Paes B, Lanari M, Rodgers-Gray B, Fullarton J, Carbonell-Estrany X. Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants. Front Pediatr. 2024 Jan 12;12:1343960. doi: 10.3389/fped.2024.1343960.

96.

Kang JM, Carbonell-Estrany X, Paes B, Rodgers-Gray B, Fullarton J, Tarride JE, Yang HJ, Chang YS, Keary I. Optimizing risk factors to guide COST-effective use of palivizumab in KOREAN infants. Pediatr Int. 2025 Jan-Dec;67(1):e70021. doi: 10.1111/ped.70021.

97.

Paes BA, Bacchini F, Bracht M, Rodgers-Gray B, Carbonell-Estrany X. Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner. Hum Vaccin Immunother. 2025 Dec;21(1):2521920. doi: 10.1080/21645515.2025.2521920. Epub 2025 Jun 24.

98.

Carbonell-Estrany X, Simões EAF, Bont L, Manzoni P, Zar HJ, Greenough A, Ramilo O, Stein R, Law B, Mejias A, Sanchez Luna M, Checchia PA, Krilov L, Lanari M, Dagan R, Fauroux B, Resch B, Heikkinen T, Domachowske JB, Wildenbeest JG, Martinon-Torres F, Thwaites R, Cetinkaya M, Alharbi AS, Rodriguez-Martinez CE, Noyola DE, Kassim A, Kusuda S, Kang JM, Rodgers-Gray B, Platonova A, Jah F, Paes B. Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in children. Expert Rev Anti Infect Ther. 2025 Jun;23(6):359-378. doi: 10.1080/14787210.2025.2481908.